you are viewing a single comment's thread.
Now this is way off base.. Comparing Docetaxel with DNDN's! Docetaxel is used for breast CA, Lung CA, Head and neck Squamous CA and gastric ca as well as prostate!!! DNDN's vaccine's only has one market!!give me a break
The current technology has only one APPROVED market..late stage prostate cancer.That market produces $3 Billion a year for SNY, but that is only half the prospective candidates.Eliminating severe side effects, as DNDN's Provenge does, will almost double that opportunity.And the kicker is the EARLY stage prostate cancer patients, plus all the other potential uses for the technology.Over time, this stock will soar.AIMHO
Hence why the insider including the CEO sold all those shares and hence the >10% drop today.